Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial

There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Control...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Diabetes care Ročník 37; číslo 8; s. 2359
Hlavní autori:	Hirakawa, Yoichiro, Arima, Hisatomi, Zoungas, Sophia, Ninomiya, Toshiharu, Cooper, Mark, Hamet, Pavel, Mancia, Giuseppe, Poulter, Neil, Harrap, Stephen, Woodward, Mark, Chalmers, John
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.08.2014
Predmet:	Aged Aged, 80 and over Blood Glucose - analysis Blood Glucose - metabolism Cause of Death Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Diabetic Angiopathies - etiology Diabetic Angiopathies - mortality Drug Combinations Female Follow-Up Studies Gliclazide - therapeutic use Humans Hypoglycemic Agents - therapeutic use Indapamide - therapeutic use Male Middle Aged Office Visits - statistics & numerical data Perindopril - therapeutic use Risk Factors
ISSN:	1935-5548, 1935-5548
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!